News

The company expects that the patent will be officially issued later in 2009, and if issued, the patent’s initial 20-year term would expire in 2024. The company said

Emtricitabine and tenofovir disoproxil fumarate tablets are the generic version of Gilead Sciences’s Truvada tablets. Truvada is a second-line anti-HIV drug in the nucleoside reverse transcriptase inhibitor family

Epiphany Biosciences, a developer of therapeutic products and diagnostic technologies that treat or help prevent the spread of pathogenic viruses, has reported that it plans to file an

This follows a licensing agreement between the two companies authorizing Ranbaxy to promote and market the drug in India. Olvance (olmesartan medoxomil) is an antihypertensive agent that can

The two new leaders will serve the company’s central and northern Illinois market operations. The announcement comes as a result of Humana’s May 2008 acquisition of OSF HealthPlans

The proceeds of the offering will be used for continued development of a suite of new products and to help fund continuing operations. The completion of the private

Switzerland-based biotechnology company ESBATech has announced encouraging preclinical results, which demonstrate efficacy of topical ESBA105, an antitumor necrosis factor single-chain antibody fragment, in a model for choroidal neovascularization.

Under the terms of this collaboration, Proteros will provide multi-disciplinary research teams with the aim of generating multiple advanced lead series inhibiting a novel proprietary target protein. In

Dr Boman comes to Acucela as a veteran of several West Coast biotech companies, most recently overseeing clinical development and regulatory affairs for Cell Therapeutics in Seattle. She